Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Baseline immunonutritional status drives CAR T-cell efficacy, survival, and safety in R/R lymphoma: validation of a pre-lymphodepletion PNI threshold.

Annals of hematology·2026
Same author

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same author

Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Frontiers in immunology·2026
Same author

Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression.

Cell reports. Medicine·2026
Same author

Immune microenvironment and its influence on CAR-T treatment outcomes in B-NHL.

Discover oncology·2026
Same author

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Blood cancer journal·2026

相关实验视频

Updated: May 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K

对耐火性/复发性扩散性大B细胞淋巴瘤进行序列CD19-20CAR T细胞疗法.

Fei Xue1, Rui Liu1, Zhonghua Fu1

  • 1Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Boren Hospital, Beijing, China.

Cytotherapy
|May 9, 2025
PubMed
概括

连续的CD19-20CAR T细胞疗法对复发性/耐药性扩散性大B细胞淋巴瘤显示出前途. 这种方法提供了有利的安全性,并增强了长期的患者反应,可能克服抗原损失问题.

关键词:
在B细胞淋巴瘤.DLBCL DLBCL 是一个字母.不同的向性CAR T细胞.持久的缓解,持续的缓解

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.8K

相关实验视频

Last Updated: May 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.2K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.8K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 血液学 血液学 血液学

背景情况:

  • 复发性/难治性扩散性大B细胞淋巴瘤 (r/r DLBCL) 的复发通常是由抗原损失和有限的CAR T细胞持久性驱动的.
  • 序列注入CD19和CD20CAR T细胞为克服这些挑战提供了一个潜在的策略.

研究的目的:

  • 评估 CD19-20 CAR T 细胞治疗在患有 r/r DLBCL 的患者中的安全性和有效性.
  • 评估这种顺序治疗对应答率和长期结果的影响.

主要方法:

  • 一项前性研究招募了21名患有r/r DLBCL的患者,这些患者接受了连续的CD19-20 CAR T细胞疗法.
  • 监测不良事件,包括细胞因子释放综合征 (CRS) 和免疫效应细胞相关的神经毒性综合征 (ICANS).
  • 治疗后评估了反应率 (部分反应 - PR,完全反应 - CR) 和反应持续时间.

主要成果:

  • 在9.5%的患者中发生了≥3级的CRS;没有观察到严重的ICANS.
  • 没有发生与治疗相关的死亡,CD20 CAR T细胞输液也没有增加严重的毒性.
  • 在90天内,61.9%的患者在CD19 CAR T细胞输液后获得PR,38.1%的患者在CD19 CAR T细胞输液后获得CR.
  • 连续的CD20CAR T细胞疗法使13名PR患者中的10人转化为CR.
  • 随访时间中位数为24.7个月,71.4%的患者保持了持续的反应.

结论:

  • 连续的CD19-20CAR T细胞疗法在r/rDLBCL中显示出良好的安全性.
  • 这种治疗方法可以通过解决抗原逃逸机制来提高长期临床结果.
  • 需要进一步的调查来证实这些有希望的发现.